Background: Many neonates with hypoxic ischemic encephalopathy and seizures do not respond to the first line antiepileptic drug, phenobarbital. Little is known about what factors are associated with its failure.
Objective: To examine factors associated with failure of phenobarbital therapy in neonates with hypoxic ischemic encephalopathy and seizures.
Design/methods: A single-center retrospective review of 50 term (>35 weeks) neonates with hypoxic ischemic encephalopathy and seizures treated with phenobarbital as the first-line antiepileptic. Neonates were classified into either responders (n = 30) or nonresponders (n = 20). Nonresponse was defined as continued seizures after maximum dosing of phenobarbital or an additional antiepileptic. Subjects with acceptable magnetic resonance imaging (MRI) scans obtained within 2 weeks of birth were included in the study and rated using an MRI injury scoring system. Charts were reviewed for demographic, clinical, and laboratory variables. Resuscitation and seizure scores were also calculated. Electroencephalographic (EEG) background activity was reviewed in 2 different time epochs (12-24 hours and 24-36 hours of life) and graded as per ACNS guidelines.
Results: There were no significant group differences in demographic, clinical, and laboratory variables except nonresponders, who had higher mean seizure score ( = .01) and significantly more injury on MRI scan for white matter ( = .004), parenchymal cortex ( = .027), and watershed ( = .009) regions. Neonates with moderately abnormal or severely abnormal background EEG responded poorly to phenobarbital.
Conclusion: In the presence of above factors, one can anticipate that additional antiepileptic medication may be needed. These data also support that larger studies should be done to look prospectively at using alternative agents first line in patients with severe injury.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/0883073819838171 | DOI Listing |
Early Hum Dev
January 2025
Department of Pediatrics, Division of Neonatology, The Hospital for Sick Children and the University of Toronto, Ontario, Canada. Electronic address:
Objectives: To build an early, prognostic model for adverse outcome in infants with hypoxic ischemic encephalopathy (HIE) receiving therapeutic hypothermia (TH) based on brain magnetic resonance images (MRI), electrophysiological tests and clinical assessments were performed during the first 5 days of life.
Methods: Retrospective study of 182 neonates with HIE and managed with TH. The predominant pattern of HIE brain injury on MRI performed following cooling was scored by neuroradiologists.
Alzheimers Dement
December 2024
Meso Scale Diagnostics, LLC., Rockville, MD, USA
Background: Three blood‐based biomarkers of neurological injury—glial fibrillary acidic protein (GFAP), neurofilament light (Nf‐L), and Tau—have emerged as promising biomarkers of neurological disorders and injuries such as hypoxic‐ischemic encephalopathy (HIE), traumatic brain injury, and Alzheimer’s disease (AD). The low levels of GFAP, Nf‐L, and Tau in serum and plasma require highly sensitive assays to detect them. Here, we report the analytical validation of an ultrasensitive, electrochemiluminescence‐based, multiplexed immunoassay for neurological biomarker assessment.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Biomed Industries, Inc., San Jose, CA, USA
Background: NA‐831 is a candidate for the treatment of Alzheimer’s Disease (AD). NA‐911 is an analog of NA‐831, serving as an IGF‐1 and GLP‐1 agonists. Animal studies of NA‐911 are evaluated for the treatment of by hypoxic‐ischemic injury, hemorrhagic stroke, and chronic neurodegenerative disorders
Method: For NA‐831: A randomized clinical trial of NA‐831 was performed in 112 participants with mild and moderate AD, half received the drugs and half received placebo.
Alzheimers Dement
December 2024
Herbert and Jackeline Krieger Klein Alzheimer’s Research Center, Rutgers Biomedical and Health Sciences, Newark, NJ, USA
Background: Hyperbaric oxygen therapy (HBOT) is a treatment in which oxygen‐enriched air (up to 100%) is administered to patients in a chamber at a pressure above one atmosphere absolute and is approved for the treatment of T2D ischemic wounds. Type 2 diabetes (T2D) is a risk factor for dementia. Ischemia due to vascular pathology is hypothesized to be an underlying mechanism for this association.
View Article and Find Full Text PDFArch Dis Child Educ Pract Ed
January 2025
Paediatric Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Neonatal encephalopathy (NE) presents as reduced consciousness, often with seizures, abnormal tone, feeding and respiratory difficulties. The most common cause is secondary to a hypoxic-ischaemic event. However, there are many important diagnoses that can also present as NE, so-called 'hypoxic ischaemic encephalopathy (HIE) mimics'.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!